Comparative Pharmacology
Head-to-head clinical analysis: RAUVAL versus SERPASIL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: RAUVAL versus SERPASIL.
RAUVAL vs SERPASIL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Rauval (rauwolfia serpentina alkaloids) depletes catecholamines and serotonin from peripheral sympathetic nerve endings and the brain by binding to and inhibiting vesicular monoamine transporters (VMAT), thus reducing sympathetic outflow. This leads to vasodilation, decreased peripheral vascular resistance, and reduced blood pressure.
Reserpine (Serpasil) is an indole alkaloid that depletes catecholamines (norepinephrine, dopamine) and serotonin from central and peripheral nerve endings by irreversibly binding to and inhibiting the vesicular monoamine transporter (VMAT), preventing storage of monoamines in presynaptic vesicles, leading to depletion and reduced sympathetic outflow.
1.5 mg orally once daily, increased to 3 mg per day if needed. Maximum dose 6 mg per day.
Hypertension: 0.1–0.25 mg orally once daily; initial dose 0.1 mg, maximum 0.5 mg/day. Psychosis (not first-line): 0.5–2 mg orally daily.
None Documented
None Documented
Terminal elimination half-life is 7-10 hours in normal renal function; prolonged to 14-20 hours in renal impairment, requiring dose adjustment.
Terminal elimination half-life 45–168 hours (mean 100 h), reflecting prolonged adrenergic depletion; clinical effects persist beyond serum presence.
Renal excretion of unchanged drug accounts for 60-70% of elimination; biliary/fecal excretion accounts for 20-30%.
Primarily renal (approx. 60% unchanged and metabolites), biliary/fecal (approx. 40%), enterohepatic circulation negligible.
Category C
Category C
Antihypertensive
Antihypertensive